Skip Navigation
Skip to contents
Filter

ARTICLE TYPE

more+
SELECT FILTER
 
Close

PUBLICATION DATE

11 results
Display

Changing landscape of diagnosis and treatment of bladder cancer

Kim WJ

No abstract available.
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Can we use methylation markers as diagnostic and prognostic indicators for bladder cancer?

Kim YJ, Kim WJ

Urothelial carcinomas of the urinary bladder have diverse biological and functional characteristics, and numerous factors are likely to be involved in recurrence, progression, and patient survival. While several molecular markers...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Autophagy and urothelial carcinoma of the bladder: A review

Chandrasekar T, Evans CP

The incidence of urothelial carcinoma of the urinary bladder (bladder cancer) remains high. While other solid organ malignancies have seen significant improvement in morbidity and mortality, there has been little...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Active surveillance for nonmuscle invasive bladder cancer

Miyake M, Fujimoto K, Hirao Y

Nonmuscle invasive bladder cancer (NMIBC) is known to be a heterogeneous malignancy that requires varying treatment modalities and follow-up schedules. Low-grade Ta papillary tumors are categorized as low-risk NMIBC because...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Aberrantly expressed microRNAs in the context of bladder tumorigenesis

Lee JY, Ryu DS, Kim WJ, Kim SJ

MicroRNAs (miRNAs), small noncoding RNAs 19-22 nucleotides in length, play a major role in negative regulation of gene expression at the posttranscriptional level. Several miRNAs act as tumor suppressors or...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
The role of microRNAs in bladder cancer

Enokida H, Yoshino H, Matsushita R, Nakagawa M

Bladder cancer (BC) is the fifth most common cancer worldwide and is associated with significant morbidity and mortality. The prognosis of muscle invasive BC is poor, and recurrence is common...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
How do we manage high-grade T1 bladder cancer? Conservative or aggressive therapy?

Yun SJ, Kim SK, Kim WJ

High-grade T1 bladder cancer has a poor prognosis due to a higher incidence of recurrence and progression than other nonmuscle invasive bladder cancer; thus patients with high-grade T1 have to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Treatment of bladder cancer in the elderly

Erlich A, Zlotta AR

As the population ages and life expectancy increases in the human population, more individuals will be diagnosed with bladder cancer (BC). The definition of who is elderly is likely to...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Immune checkpoint blockade therapy for bladder cancer treatment

Kim J

Bladder cancer remains the most immunogenic and expensive malignant tumor in the United States today. As the 4th leading cause of death from cancer in United States, Immunotherapy blocking immune...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Dietary factors associated with bladder cancer

Piyathilake C

It is biologically plausible for dietary factors to influence bladder cancer risk considering that beneficial as well as harmful components of a diet are excreted through the urinary tract and...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close
Open versus robotic cystectomy: Comparison of outcomes

Davis RB, Farber NJ, Tabakin AL, Kim IY, Elsamra SE

Open radical cystectomy (ORC) is the current gold standard treatment for muscle invasive bladder cancer. As surgeons become more proficient in minimally invasive and robotic surgical techniques, the number of...
CITED
export Copy
Close
SHARE
Twitter Facebook
Close

Go to Top

Copyright © 2024 by Korean Association of Medical Journal Editors. All rights reserved.     E-mail: koreamed@kamje.or.kr